Tag: Diabetes UK

Latest articles

Image of four people communicating via different mediums to depict mind the Generation Gap in pharma marketing

Mind the generation gap in pharma marketing and market research

Industry came together to explore the impact of the generation gap in pharma marketing and market research at BHBIA's summer event. Different generations have always...
AstraZeneca presents results from Phase III TULIP 2 trial for anifrolumab

AstraZeneca presents anifrolumab results from Phase III TULIP trial

Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...

Popular articles

Scottish flag showing Novartis advanced breast cancer treatment approved in Scotland

Novartis advanced breast cancer treatment approved in Scotland

Novartis’ Kisqali® (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium as advanced breast cancer treatment for patients with the most common...
Peter Hyde: Myths busting remote sales solutions

Myth busting remote sales solutions

Peter Hyde, Managing Director at Alveo Solutions, looks at the common myths and deciphers the reality of remote sales solutions. The industry is increasingly adopting remote...
Mapping NHS change is key to customer engagement

Mapping NHS change is key to customer engagement

Simon Grime, of Wilmington Healthcare, explains how mapping NHS change through data and intelligence can help industry understand and engage customers in the new...
AstraZeneca presents results from Phase III TULIP 2 trial for anifrolumab

AstraZeneca presents anifrolumab results from Phase III TULIP trial

Results from the positive Phase III TULIP 2 trial for AstraZeneca's anifrolumab, a potential new medicine for the treatment of moderate to severe systemic...
Astellas Pharma announces acceptance by EMA of a Type II Variation Application for regulatory review for the use of XTANDI™ (enzalutamide) in mHSPC patients

AstraZeneca to appeal NICE’s osimertinib decision

AstraZeneca to appeal NICE's osimertinib decision following it not being recommended for use within NHS England. AstraZeneca will appeal a decision by the National Institute...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription